Caffo, Orazio Messina, Marco Veccia, Antonello Kinspergher, Stefania Maines, Francesca Messina, Carlo
Published in
Critical Reviews in Oncology/Hematology
Real-world data suggest a possible interplay between androgen deprivation therapy (ADT) and susceptibility to and the severity of SARS-CoV-2 infection. As ADT is the backbone of prostate cancer treatment, various authors have evaluated different patient cohorts but the evidence provided is conflicting. The aim of this review is to assess the availa...
Wang, YouZhi Wu, Ning Jiang, Ning
Published in
Cell Death & Disease
Prostate cancer is a common malignant tumor, which can spread to multiple organs in the body. Metastatic disease is the dominant reason of death for patients with prostate cancer. Prostate cancer usually transfers to bone. Bone metastases are related to pathologic fracture, pain, and reduced survival. There are many known targets for prostate cance...
Dieperink, Karin B Hansen, Steinbjørn Wagner, Lis Minet, Lisbeth R Hansen, Olfred
Published in
Journal of cancer survivorship : research and practice
In the Rehabilitation of Prostate Cancer (RePCa) study, the intervention reduced early adverse effects in prostate cancer 6 months after radiotherapy. This 3-year follow-up study assesses late adverse effects, evaluates rehabilitative long-term effects and identifies patients who benefit the most. RePCa was a randomized clinical trial with multidis...
Yang, David D Nguyen, Paul L
Published in
Urologic oncology
Radiation therapy with androgen deprivation therapy (ADT) has historically been one of the mainstays of treatment for intermediate- and high-risk prostate cancer. The benefit of ADT likely derives from both enhancing local control and inhibiting micrometastatic disease. While level 1 evidence has demonstrated the benefits of 4-6 months of ADT for a...
Kopelke, Svenja Bartscht, Tobias Schild, Steven E Tvilsted, Soeren Kjaer, Troels W Rades, Dirk
Published in
Anticancer research
Many patients with prostate cancer receive definitive or adjuvant radiotherapy. This study aimed to identify the frequency of sleep disturbances and corresponding risk factors prior to radiation treatment. Data of 48 patients assigned to local or loco-regional irradiation for prostate cancer were retrospectively analyzed for pre-radiotherapy sleep ...
Bertolo, R Vittori, M Cipriani, C Maiorino, F Forte, V Iacovelli, V Petta, F Sperandio, M Marani, C Panei, M
...
Published in
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
We aimed to compare the pathway including multi-parametric Magnetic Resonance Imaging (mpMRI) versus the one without mpMRI in detection of prostate cancer (PCa) when mpMRI is not centralized. January 2019-March 2020: prospective data collection of trans-perineal prostate biopsies. Group A: biopsy-naïve patients who underwent mpMRI (at any instituti...
Csizmarik, Anita Hadaschik, Boris Kramer, Gero Nyirady, Peter Szarvas, Tibor
Published in
Urologic oncology
Next-generation androgen signaling inhibitors such as abiraterone and enzalutamide are widely used for the treatment of metastatic castration-resistant prostate cancer. Unfortunately, baseline and acquired resistance to these treatments is commonly observed. In the last few years, significant effort has been devoted to uncover the molecular mechani...
Verco, Shelagh Maulhardt, Holly Baltezor, Michael Williams, Emily Iacobucci, Marc Wendt, Alison Verco, James Marin, Alyson Campbell, Sam Dorman, Paul
...
Published in
Drug delivery and translational research
This report describes local administration of submicron particle paclitaxel (SPP) (NanoPac®: ~ 800-nm-sized particles with high relative surface area with each particle containing ~ 2 billion molecules of paclitaxel) in preclinical models and clinical trials evaluating treatment of carcinomas. Paclitaxel is active in the treatment of epithelial sol...
Li, Eric V Siddiqui, Mohammad R Weiner, Adam B Prizment, Anna E Ryan, Charles J Morgans, Alicia K
Published in
Clinical genitourinary cancer
Combination therapy with docetaxel and androgen deprivation therapy (ADT) prolongs overall survival (OS) in men with metastatic hormone-sensitive prostate cancer. We assessed the benefits and adverse effects of docetaxel and ADT in relation to advancing age. We performed a post hoc analysis of the CHAARTED trial comparing docetaxel and ADT vs. ADT ...
Pelloux-Prayer, Rémi Schiele, Philomène Oudard, Stéphane Gravis, Gwenaëlle Kleinclauss, François Crehange, Gilles Hennequin, Christophe Morgans, Alicia K Geoffrois, Lionel Limat, Samuel
...
Published in
Clinical genitourinary cancer
The optimal therapeutic strategies for patients with metastatic hormone-sensitive prostate cancer (mHSPC) followed by metastatic castrate-resistant prostate cancer (mCRPC), in terms of cost and effectiveness, remains unknown. This study aims to compare the cost-effectiveness of various potential strategies, from the start of first-line treatment in...
